R
Renovion
Pre-clinical stage pharmaceutical company
About Renovion
Renovion is a clinical stage pharmaceutical company specializing in nebulized therapies aimed at restoring mucus clearance and reducing inflammation in the lungs. The company's flagship product, ARINA-1, is designed to treat orphan chronic inflammatory lung diseases such as lung transplant complications, cystic fibrosis (CF), and non-CF bronchiectasis. With over 25 patient years of experience, ARINA-1 is set to enter clinical trials, targeting both lung transplant patients and those suffering from CF and non-CF bronchiectasis. Renovion operates in the pharmaceutical and healthcare market, focusing on niche, high-need areas where current treatments are inadequate. The company primarily serves patients with severe lung conditions, offering a specialized solution that aims to improve their quality of life. The business model revolves around the development and eventual commercialization of ARINA-1, generating revenue through the sale of this proprietary therapy. Renovion plans to initiate a New Drug Application (NDA) enabling clinical trial for lung transplant patients and proof-of-concept studies for CF and non-CF bronchiectasis in 2020.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Chapel Hill, United States
- Employees
- 6
- Open positions
- None listed
- Dealroom signal
- 77.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Dec 2022 | $15M | $60M | Undisclosed | ↗ |
| SERIES A✓Equity / VC | Jun 2020 | $8.1M | $32M | Whale Rock Capital Management | — |
Growth signals
Latest recorded traffic for Renovion is 3.9K monthly website visits, up 77.3% over the last three months. Renovion's team grew 20% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Whale Rock Capital Management
Other known investors1 additional known investor
University of North Carolina at Chapel Hill
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Renovion on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Renovion’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.